Substance P

Elevated Substance P levels would primarily manifest as an amplification of pain signaling and inflammatory sensation. Ordinary stimuli would carry an unpleasant intensity. Emotional distress would feel more acute and harder to modulate. There might be a sense of anxious vulnerability, as Substance P plays a role in the stress response. Nausea could intensify. The experience would resemble a state of heightened sensitivity where both physical and emotional pain are turned up in volume.

Structure and Synthesis

Substance P (SP) has the sequence: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂. It is synthesized from the preprotachykinin A (PPTA) gene, which also encodes neurokinin A (NKA) and neuropeptide K. Substance P is concentrated in small-diameter primary afferent neurons (C-fibers and some Aδ-fibers), in the enteric nervous system (making the gut a major peripheral reservoir), and in multiple CNS regions including the striatum, hypothalamus, amygdala, and brainstem.

Neurokinin Receptors

Substance P acts at three neurokinin (NK) receptor subtypes, all GPCRs coupled to Gq/11 (phospholipase C activation, IP3/DAG second messengers, intracellular calcium mobilization):

• NK1 receptors — highest affinity for Substance P; primary functional target. NK1 is expressed on postsynaptic neurons in the spinal dorsal horn (pain processing), in the area postrema (nausea/vomiting center), in limbic regions (amygdala, hippocampus — relevant to emotional responses), and extensively in the gut (enteric nervous system)
• NK2 receptors — highest affinity for neurokinin A; primarily peripheral, smooth muscle
• NK3 receptors — highest affinity for neurokinin B; primarily central, involved in thermoregulation and mood

Pain Signaling: Central Sensitization

In the spinal dorsal horn, Substance P co-released with glutamate activates NK1 receptors on projection neurons. Unlike ionotropic glutamate receptor activation (fast, short-duration), NK1 activation produces sustained, slow-onset depolarization. With repeated or intense stimulation, this sustained NK1 activation contributes to central sensitization — a state of enhanced responsiveness in dorsal horn neurons characterized by:

• Lowered activation threshold (allodynia — pain from normally non-painful stimuli)
• Amplified responses to suprathreshold stimuli (hyperalgesia)
• Spontaneous activity
• Expanded receptive fields

Central sensitization is the neurological substrate of chronic pain conditions (fibromyalgia, chronic back pain, complex regional pain syndrome) and of the pain hypersensitivity that follows injury.

Nausea and the Area Postrema

The area postrema (AP) is a circumventricular organ in the brainstem lacking a blood-brain barrier, allowing it to sample blood for emetic triggers. It contains high densities of NK1 receptors, serotonin 5-HT3 receptors (both major antiemetic drug targets), and dopamine D2 receptors. Substance P in the AP mediates the nausea and vomiting associated with:

• Chemotherapy and radiation therapy
• Opioid-induced nausea
• Motion sickness (interacts with vestibular input)
• Possibly, psychedelic-induced nausea (5-mushroom nausea may also involve gut serotonin)

Inflammation and Neurogenic Inflammation

Peripheral Substance P release from C-fiber terminals in inflamed tissue produces neurogenic inflammation — vasodilation and plasma extravasation ("flare and wheal") via NK1 receptors on blood vessels. SP also activates mast cells (releasing histamine and other inflammatory mediators) and recruits immune cells. This peripheral inflammatory loop amplifies and sustains local inflammation following tissue damage.

CNS Roles: Stress and Mood

Beyond pain and nausea, Substance P in limbic regions (amygdala, hippocampus) modulates emotional responses to stress. High levels of SP and NK1 receptors are found in the amygdala's central nucleus. NK1 receptor antagonists have shown antidepressant effects in some human clinical trials — suggesting a role for SP in mood regulation beyond its well-established pain functions. The NK1 system appears to be part of the brain's response to social defeat and psychological stress.

Discovery

Substance P was first detected in 1931 by John Henry Gaddum and Viktor Mutt, who found that extracts of equine intestine and brain tissue contained a substance that caused smooth muscle contractions and blood pressure drops — effects distinct from acetylcholine and adrenaline. The active material was present in dry powder preparations, leading to its designation as "Substance P." The name was not intended to stand for "pain" — that association came later as its role in nociception became clear.

Characterization of Structure

It took four decades to fully characterize Substance P's chemical structure. It was identified as an undecapeptide (11 amino acids) by Ulf von Euler and John Gaddum, and its full amino acid sequence was determined in 1970 by Michael Chang and Leroy Leeman at the University of Edinburgh. The sequence Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ placed it in the tachykinin family (characterized by the C-terminal sequence Phe-X-Gly-Leu-Met-NH₂), along with later-characterized members kassinin and eledoisin.

Capsaicin and the Pain Connection

The connection between Substance P and pain signaling was established through studies of capsaicin in the 1970s and 1980s. Nicholas Jancsó at the University of Szeged showed that neonatal capsaicin treatment depleted Substance P from C-fiber neurons and produced lasting analgesia. This established Substance P as a primary chemical mediator of C-fiber-mediated pain and triggered decades of research into NK1 receptor antagonists as analgesics.

NK1 Antagonists: Clinical Development

The development of NK1 receptor antagonists as potential analgesics and antidepressants was a major pharmaceutical research effort from the 1990s onward. MK-869 (aprepitant) was originally developed as an antidepressant — showing early promise in clinical trials. However, larger Phase III trials failed to demonstrate consistent antidepressant efficacy, and development pivoted to the antiemetic indication. Aprepitant was approved by the FDA in 2003 for chemotherapy-induced nausea and vomiting — the first NK1 antagonist to reach the market. The antidepressant story for NK1 antagonists remains open, with ongoing investigation.